Literature DB >> 23637041

Distribution of Streptococcus pneumoniae serotypes that cause parapneumonic empyema in Turkey.

Mehmet Ceyhan1, Yasemin Ozsurekci, Nezahat Gürler, Sengul Ozkan, Gulnar Sensoy, Nursen Belet, Mustafa Hacimustafaoglu, Solmaz Celebi, Melike Keser, Ener Cagri Dinleyici, Emre Alhan, Ali Baki, Ahmet Faik Oner, Hakan Uzun, Zafer Kurugol, Ahmet Emre Aycan, Venhar Gurbuz, Eda Karadag Oncel, Melda Celik, Aslinur Ozkaya Parlakay.   

Abstract

Streptococcus pneumoniae is the most common etiological cause of complicated pneumonia, including empyema. In this study, we investigated the serotypes of S. pneumoniae that cause empyema in children. One hundred fifty-six children who were diagnosed with pneumonia complicated with empyema in 13 hospitals in seven geographic regions of Turkey between 2010 and 2012 were included in this study. Pleural fluid samples were collected by thoracentesis and tested for 14 serotypes/serogroups using a Bio-Plex multiplex antigen detection assay. The serotypes of S. pneumoniae were specified in 33 of 156 samples. The mean age ± the standard deviation of the 33 patients was 6.17 ± 3.54 years (range, 0.6 to 15 years). All of the children were unvaccinated according to the vaccination reports. Eighteen of the children were male, and 15 were female. The serotypes of the non-7-valent pneumococcal conjugated vaccine (non-PCV-7), serotype 1, serotype 5, and serotype 3, were detected in eight (14.5%), seven (12.7%), and five (9.1%) of the samples, respectively. Serotypes 1 and 5 were codetected in two samples. The remaining non-PCV-7 serotypes were 8 (n = 3), 18 (n = 1), 19A (n = 1), and 7F/A (n = 1). PCV-7 serotypes 6B, 9V, 14, 19F, and 23F were detected in nine (16.3%) of the samples. The potential serotype coverages of PCV-7, PCV-10, and PCV-13 were 16.3%, 45.4%, and 60%, respectively. Pediatric parapneumonic empyema continues to be an important health problem despite the introduction of conjugated pneumococcal vaccines. Active surveillance studies are needed to monitor the change in S. pneumoniae serotypes that cause empyema in order to have a better selection of pneumococcal vaccines.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23637041      PMCID: PMC3697447          DOI: 10.1128/CVI.00765-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  42 in total

1.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.

Authors:  S Black; H Shinefield; B Fireman; E Lewis; P Ray; J R Hansen; L Elvin; K M Ensor; J Hackell; G Siber; F Malinoski; D Madore; I Chang; R Kohberger; W Watson; R Austrian; K Edwards
Journal:  Pediatr Infect Dis J       Date:  2000-03       Impact factor: 2.129

2.  An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations.

Authors:  Carrie L Byington; LaShonda Y Spencer; Timothy A Johnson; Andrew T Pavia; Daniel Allen; Edward O Mason; Sheldon Kaplan; Karen C Carroll; Judy A Daly; John C Christenson; Matthew H Samore
Journal:  Clin Infect Dis       Date:  2002-01-03       Impact factor: 9.079

3.  Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.

Authors:  Otto G Vanderkooi; David W Scheifele; Douglas Girgenti; Scott A Halperin; Scott D Patterson; William C Gruber; Emilio A Emini; Daniel A Scott; James D Kellner
Journal:  Pediatr Infect Dis J       Date:  2012-01       Impact factor: 2.129

4.  Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  J Pekka Nuorti; Cynthia G Whitney
Journal:  MMWR Recomm Rep       Date:  2010-12-10

5.  Pneumococcal serotypes causing pediatric meningitis in Turkey: application of a new technology in the investigation of cases negative by conventional culture.

Authors:  M Ceyhan; I Yildirim; C L Sheppard; R C George
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-01-20       Impact factor: 3.267

6.  Pediatric parapneumonic empyema: risk factors, clinical characteristics, microbiology, and management.

Authors:  Galia Grisaru-Soen; Michal Eisenstadt; Gideon Paret; David Schwartz; Nathan Keller; Hagit Nagar; Shimon Reif
Journal:  Pediatr Emerg Care       Date:  2013-04       Impact factor: 1.454

7.  Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae.

Authors:  Tina Q Tan; Edward O Mason; Ellen R Wald; William J Barson; Gordon E Schutze; John S Bradley; Laurence B Givner; Ram Yogev; Kwang Sik Kim; Sheldon L Kaplan
Journal:  Pediatrics       Date:  2002-07       Impact factor: 7.124

8.  Five-fold increase in pediatric parapneumonic empyema since introduction of pneumococcal conjugate vaccine.

Authors:  Debra J Hendrickson; Dean A Blumberg; Jesse P Joad; Sanjay Jhawar; Ruth J McDonald
Journal:  Pediatr Infect Dis J       Date:  2008-11       Impact factor: 2.129

9.  Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia.

Authors:  Steven B Black; Henry R Shinefield; Stella Ling; John Hansen; Bruce Fireman; David Spring; Jack Noyes; Edwin Lewis; Paula Ray; Janelle Lee; Jill Hackell
Journal:  Pediatr Infect Dis J       Date:  2002-09       Impact factor: 2.129

10.  Association of serotype of Streptococcus pneumoniae with risk of severe and fatal outcome.

Authors:  Simon Rückinger; Rüdiger von Kries; Annette Siedler; Mark van der Linden
Journal:  Pediatr Infect Dis J       Date:  2009-02       Impact factor: 2.129

View more
  10 in total

1.  Meningitis caused by Neisseria Meningitidis, Hemophilus Influenzae Type B and Streptococcus Pneumoniae during 2005-2012 in Turkey. A multicenter prospective surveillance study.

Authors:  Mehmet Ceyhan; Nezahat Gürler; Yasemin Ozsurekci; Melike Keser; Ahmet Emre Aycan; Venhar Gurbuz; Nuran Salman; Yildiz Camcioglu; Ener Cagri Dinleyici; Sengul Ozkan; Gulnar Sensoy; Nursen Belet; Emre Alhan; Mustafa Hacimustafaoglu; Solmaz Celebi; Hakan Uzun; Ahmet Faik Oner; Zafer Kurugol; Mehmet Ali Tas; Denizmen Aygun; Eda Karadag Oncel; Melda Celik; Olcay Yasa; Fatih Akin; Yavuz Coşkun
Journal:  Hum Vaccin Immunother       Date:  2014-11-17       Impact factor: 3.452

2.  Serotype distribution of Streptococcus pneumoniae in children with invasive diseases in Turkey: 2008-2014.

Authors:  Mehmet Ceyhan; Yasemin Ozsurekci; Nezahat Gürler; Lütfiye Öksüz; Sohret Aydemir; Sengul Ozkan; Serife Yuksekkaya; Melike Keser Emiroglu; Meral Gültekin; Akgün Yaman; Abdurrahman Kiremitci; Keramettin Yanık; Arzu Karli; Hatice Ozcinar; Faruk Aydin; Gulcin Bayramoglu; Yasemin Zer; Zeynep Gulay; Efgan Dogan Gayyurhan; Mustafa Gül; Cüneyt Özakın; Hüseyin Güdücüoğlu; Duygu Perçin; Nezahat Akpolat; Candan Ozturk; Yıldız Camcıoğlu; Eda Karadağ Öncel; Melda Çelik; Laser Şanal; Hakan Uslu
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

3.  An ahemolytic pneumolysin of Streptococcus pneumoniae manipulates human innate and CD4⁺ T-cell responses and reduces resistance to colonization in mice in a serotype-independent manner.

Authors:  M Nadeem Khan; John Robert Coleman; Joshua Vernatter; Avanish Kumar Varshney; Chad Dufaud; Liise-Anne Pirofski
Journal:  J Infect Dis       Date:  2014-06-13       Impact factor: 5.226

4.  Pneumococcal carriage in children with COVID-19.

Authors:  Kubra Aykac; Yasemin Ozsurekci; Burcu Ceylan Cura Yayla; Kubra Evren; Sibel Lacinel Gurlevik; Pembe Derin Oygar; Mihriban Yucel; Ayse Esra Karakoc; Alpaslan Alp; Ali Bulent Cengiz; Mehmet Ceyhan
Journal:  Hum Vaccin Immunother       Date:  2021-01-15       Impact factor: 3.452

Review 5.  Pneumococcal empyema and complicated pneumonias: global trends in incidence, prevalence, and serotype epidemiology.

Authors:  M A Fletcher; H-J Schmitt; M Syrochkina; G Sylvester
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-23       Impact factor: 3.267

6.  Direct Streptococcus pneumoniae real-time PCR serotyping from pediatric parapneumonic effusions.

Authors:  Robert Slinger; Lucie Hyde; Ioana Moldovan; Francis Chan; Jeffrey M Pernica
Journal:  BMC Pediatr       Date:  2014-07-24       Impact factor: 2.125

7.  Empyema due to Streptococcus Pneumoniae Serotype 9V in a Child Immunized with 13-Valent Conjugated Pneumococcal Vaccine.

Authors:  Murat Sütçü; Hacer Aktürk; Fatih Karagözlü; Ayper Somer; Nezahat Gürler; Nuran Salman
Journal:  Balkan Med J       Date:  2017-01-05       Impact factor: 2.021

Review 8.  Surveillance of pneumococcal diseases in Central and Eastern Europe.

Authors:  Mehmet Ceyhan; Ron Dagan; Abdullah Sayiner; Liudmyla Chernyshova; Ener Çağrı Dinleyici; Waleria Hryniewicz; Andrea Kulcsár; Lucia Mad'arová; Petr Pazdiora; Sergey Sidorenko; Anca Streinu-Cercel; Arjana Tambić-Andrašević; Lyazzat Yeraliyeva
Journal:  Hum Vaccin Immunother       Date:  2016-04-20       Impact factor: 3.452

9.  Etiology of parapneumonic effusion and pleural empyema in children. The role of conventional and molecular microbiological tests.

Authors:  Katarzyna Krenke; Ewa Sadowy; Edyta Podsiadły; Waleria Hryniewicz; Urszula Demkow; Marek Kulus
Journal:  Respir Med       Date:  2016-05-10       Impact factor: 3.415

10.  Serotype distribution of Streptococcus pneumonia in children with invasive disease in Turkey: 2015-2018.

Authors:  Mehmet Ceyhan; Kubra Aykac; Nezahat Gurler; Yasemin Ozsurekci; Lütfiye Öksüz; Özlem Altay Akısoglu; Fatma Nur Öz; Melike Emiroglu; Hatice TurkDagi; Akgün Yaman; Güner Söyletir; Candan Öztürk; Nezahat Akpolat; Cüneyt Özakin; Faruk Aydın; Şöhret Aydemir; Abdurrahman Kiremitci; Meral Gültekin; Yıldız Camcıoglu; Yasemin Zer; Hüseyin Güdücüoğlu; Zeynep Gülay; Asuman Birinci; Cigdem Arabaci; Adem Karbuz; Ilker Devrim; Yelda Sorguc; Betil Özhak Baysan; Eda Karadag Oncel; Nisel Yilmaz; Yasemin Ay Altintop
Journal:  Hum Vaccin Immunother       Date:  2020-06-12       Impact factor: 3.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.